Challenge:
A biopharma start-up developing a small molecule to treat a rare kidney disorder sought Alacrita’s advice on its Target Product Profile (TPP) and market attractiveness. Specifically, they wanted feedback from payers on a realistic pricing window and to understand the market access challenges and opportunities for its drug.
Solution:
First, Alacrita reviewed documentation outlining information about the product and the associated TPP provided by the company. Alacrita performed orphan landscape mapping in the US and key EU countries, highlighting similar products by disease burden and dosing. We subsequently conducted a benchmarking analysis to build a picture of comparable products and prices. We then tested the differentiation of the company’s product from current treatments with payers, obtaining their views on its value given the disease burden and prospective pricing for the product. We assessed the evidence required to support the proposed pricing and preferred formulary position. On completion of the project, we compiled our analyses and conclusions in a report which was used by the client in discussions with investors and potential partners.
New Product Planning
The payer environment for innovative therapies is becoming increasingly competitive. Leverage our team’s industry experience in pharmaceutical market access, market research and strategic planning. We will work with you to map a clear path towards optimized access and value-based pricing for your new products. Alacrita’s expert network also offers you access to senior Medical Affairs experience, which we have used to help clients drive alignment at the commercial and medical interface.